feed,title,long_url,short_url
Benzinga,"With Karuna Therapeutics $14B Deal, Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio: Analyst",https://benzinga.com/analyst-ratings/analyst-color/23/12/36365959/with-karuna-therapeutics-14b-deal-bristol-myers-is-serious-for-re-establishing-its-,https://da.gd/pa9z
